HC Wainwright Predicts Merus’ FY2029 Earnings (NASDAQ:MRUS)

Merus (NASDAQ:MRUS) – Research analysts at HC Wainwright raised their FY2029 EPS estimates for shares of Merus in a research note issued to investors on Thursday, May 8th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings per share of $0.81 for the year, up from their prior estimate of $0.80. HC Wainwright has a “Buy” rating and a $85.00 price objective on the stock. The consensus estimate for Merus’ current full-year earnings is ($3.85) per share.

Merus (NASDAQ:MRUS) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.23). The firm had revenue of $26.49 million for the quarter, compared to the consensus estimate of $7.82 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%.

Several other equities research analysts have also recently commented on the company. Bank of America dropped their price objective on Merus from $73.00 to $70.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. Piper Sandler initiated coverage on shares of Merus in a report on Thursday, February 13th. They set an “overweight” rating and a $84.00 price objective for the company. William Blair restated an “outperform” rating on shares of Merus in a report on Monday, April 28th. Needham & Company LLC reiterated a “buy” rating and set a $83.00 target price on shares of Merus in a research note on Wednesday, April 9th. Finally, Wells Fargo & Company dropped their price target on Merus from $91.00 to $89.00 and set an “overweight” rating on the stock in a research note on Thursday. One investment analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $85.15.

Merus Trading Down 3.4 %

Merus stock opened at $41.32 on Friday. Merus has a 12 month low of $33.19 and a 12 month high of $61.61. The stock has a fifty day simple moving average of $43.58 and a two-hundred day simple moving average of $44.23. The firm has a market cap of $2.86 billion, a price-to-earnings ratio of -10.46 and a beta of 0.94.

Hedge Funds Weigh In On Merus

Several large investors have recently added to or reduced their stakes in MRUS. GAMMA Investing LLC increased its stake in shares of Merus by 2,153.6% in the first quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 603 shares in the last quarter. State of Wyoming bought a new position in Merus in the 4th quarter worth $48,000. Wells Fargo & Company MN increased its stake in Merus by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock worth $59,000 after buying an additional 300 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Merus during the fourth quarter valued at about $60,000. Finally, Avior Wealth Management LLC purchased a new position in shares of Merus in the fourth quarter valued at about $76,000. Hedge funds and other institutional investors own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.